Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -52.47% is 219% below its 5-year average of -16.46%, near the high end of its 5-year range (-397.26%–36.57%).
As of the fiscal period ended Tuesday, June 30, 2026. 42.03% below its 12-month average of -36.94%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -52.47%.
RETURN ON EQUITY (ROE)
-52.47%
RETURN ON EQUITY (ROE) AVG TTM
-36.94%
RETURN ON EQUITY (ROE) AVG 3Y
-27.12%
RETURN ON EQUITY (ROE) AVG 5Y
-16.46%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-42.03%
CURRENT VS 3Y AVG
-93.46%
CURRENT VS 5Y AVG
-218.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 621 covered companies
CURRENT VS SECTOR MEDIAN
-30.53%
vs the sector median at left
Immatics N.V.
Market Cap
$1.04B
Return on Equity (ROE)
-52.47%
TTM Avg
-36.94%
3Y Avg
-27.12%
5Y Avg
-16.46%
Market Cap
$1.04B
Return on Equity (ROE)
-4.13%
TTM Avg
-0.56%
3Y Avg
-8.16%
5Y Avg
-7.12%
Market Cap
$1.04B
Return on Equity (ROE)
-11.06%
TTM Avg
-9.32%
3Y Avg
-13.81%
5Y Avg
-2.96%
Market Cap
$1.03B
Return on Equity (ROE)
-0.69%
TTM Avg
-24.98%
3Y Avg
-8.92%
5Y Avg
-2.80%
Market Cap
$1.05B
Return on Equity (ROE)
-13.54%
TTM Avg
-40.81%
3Y Avg
-170.75%
5Y Avg
-114.78%
Market Cap
$1.07B
Return on Equity (ROE)
-63.62%
TTM Avg
-41.08%
3Y Avg
-23.78%
5Y Avg
-22.76%
Market Cap
$1.02B
Return on Equity (ROE)
-4.51%
TTM Avg
-33.13%
3Y Avg
-42.62%
5Y Avg
-42.62%
Market Cap
$1.01B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$998.31M
Return on Equity (ROE)
-25.78%
TTM Avg
29.18%
3Y Avg
31.59%
5Y Avg
31.59%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immatics N.V. (IMTX) | $1.04B | -52.47% | -36.94% | -27.12% | -16.46% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | -4.13% | -0.56% | -8.16% | -7.12% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.04B | -11.06% | -9.32% | -13.81% | -2.96% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | -0.69% | -24.98% | -8.92% | -2.80% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -13.54% | -40.81% | -170.75% | -114.78% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.07B | -63.62% | -41.08% | -23.78% | -22.76% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | -4.51% | -33.13% | -42.62% | -42.62% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.01B | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $998.31M | -25.78% | 29.18% | 31.59% | 31.59% |
| IRadimed Corporation (IRMD)vs › | $1.09B | 22.66% | 22.95% | 21.85% | 17.09% |
ROE
-52.5%
ROA
-43.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -52.47% |
| 2026-03-31 | -47.61% |
| 2025-12-31 | -39.97% |
| 2025-09-30 | -28.40% |
| 2025-06-30 | -16.27% |
| 2025-03-31 | -4.39% |
| 2024-12-31 | 2.56% |
| 2024-09-30 | -14.11% |
| 2024-06-30 | -18.91% |
| 2024-03-31 | -19.92% |
| 2023-12-31 | -43.77% |
| 2023-09-30 | -34.52% |
| 2023-06-30 | -34.84% |
| 2023-03-31 | -32.61% |
| 2022-12-31 | 19.94% |
| 2022-09-30 | 36.57% |
| 2022-06-30 | 22.56% |
| 2022-03-31 | 9.93% |
| 2021-12-31 | -397.26% |
| 2021-09-30 | -274.34% |
| 2021-06-30 | -300.47% |
| 2021-03-31 | -240.68% |
| 2020-12-31 | -231.28% |
| 2020-09-30 | -169.35% |
